AstraZeneca trials show antibody drug more than 80% effective at preventing COVID-19
Fox News
COVID-19 vaccine maker AstraZeneca announced Thursday that its antibody drug is more than 80% effective at reducing risk of severe disease or death.
Analysis of the ongoing Provent trial with a six-month follow-up found that one 300- mg intramuscular dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%.
"The AZD7442 PROVENT trial is the first Phase III trial prospectively designed to evaluate a monoclonal antibody for pre-exposure prophylaxis of symptomatic COVID-19, with targeted inclusion of high-risk and immunocompromised participants. More than 75% of PROVENT participants at baseline had co-morbidities that put them at high risk for severe COVID-19 if they were to become infected, including people who are immunocompromised and may have a reduced immune response to vaccination," AstraZeneca wrote.